

FORM 51-102F3

Material Change Report

Item 1. Name and Address of Company

Blackhawk Growth Corp. (the “Company”)
Suite 2200, 885 West Georgia Street
Vancouver, B.C., V6C 3E8

Item 2. Date of Material Change

News Release dated September 22, 2022

Item 3. News Release

The Company disseminated a news release concerning the material change described herein on September 22, 2022 and subsequently filed a copy on SEDAR at www.sedar.com.

Item 4. Summary of Material Change

Blackhawk’s MindBio nominated for Company of the Year by industry peers as it prepares for Phase 2 clinical trials.

- MindBio nominated for prestigious awards including Company of the Year and LSD Company of the Year.
- MindBio Co-Founder Justin Hanka nominated for two awards: Entrepreneur of the Year and Innovator of the Year.

Item 5. Full Description of Material Change

Vancouver, British Columbia – September 22, 2022 – Blackhawk Growth Corp (CSE:BLR; Frankfurt:0JJ) (the “**Company**” or “**Blackhawk**”) is pleased to report that its subsidiary, MindBio Therapeutics (“MindBio”), and its Co-Founder Justin Hanka, have been nominated for a number of annual awards by global industry peers in the annual Microdose Awards.

Investors can vote for MindBio and Co-Founder Justin Hanka [here](#)

MindBio has been nominated in the category of Company of the Year alongside industry leaders Cybin, Dr. Bronner’s, Microdose Therapeutics and Psilera. MindBio is also nominated in the category for LSD Company of the Year alongside Beckley Psytech, BetterLife Pharma, MindMed and Psygen.

MindBio’s Co-Founder Justin Hanka has been nominated for Entrepreneur of the Year alongside industry leaders Christian Angermayer, David Champion, Iri Selkirk and Chris Witowski.

Mr Hanka has also been nominated in the category of Innovator of the Year alongside industry leaders Najla Guthrie, Dr. Darryl Hudson, Lars Christian Wilde and Jacki Von Salm.

The awards will be presented at the upcoming Wonderland Convention in Miami in November.

MindBio is also pleased to announce that preparations are well underway for the start of their Phase 2 Clinical trials and further announcements will be made after the presentation and reveal of data from their Phase 1 LSD Microdosing Clinical Trials in 80 healthy subjects.

“MindBio is leading the way in psychedelic microdosing clinical trials. With the recent successful completion of MindBio’s Phase 1 clinical trial, the MindBio team is now preparing for Phase 2 Clinical Trials and progressing its work with a strong focus towards commercialization,” said Frederick Pels, CEO of Blackhawk.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States.

For further information please contact:

Frederick Pels, Chief Executive Officer
(403)-991-7737
fred@blackhawkgrowth.com

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable

Item 7. Omitted Information
Not applicable

Item 8. Executive Officer

The following senior officer of the Company is knowledgeable about the material change disclosed in this report.

Frederick Pels
Chief Executive Officer
Telephone: 403-991-7737

Item 9. Date of Report

September 22, 2022